Hepatic arterial chemotherapy with raltitrexed and oxaliplatin versus standard chemotherapy in unresectable liver metastases from colorectal cancer after conventional chemotherapy failure (HEARTO): a randomized phase-II study.

Fiche publication

Date publication

juillet 2019

Journal

Journal of cancer research and clinical oncology

Auteurs

Membres identifiés du Cancéropôle Est :
Dr BERTAUT Aurélie , Pr BORG Christophe , Pr GHIRINGHELLI François , Dr JOUVE Jean-Louis , Dr VINCENT Julie , Pr LOFFROY Romaric , Dr BENGRINE-LEFEVRE Leila

Tous les auteurs :
Ghiringhelli F, Vincent J, Bengrine L, Borg C, Jouve JL, Loffroy R, Guiu B, Blanc J, Bertaut A

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/31273511

Résumé

Hepatic arterial infusion (HAI) of chemotherapy could be used in patients with liver-only metastatic colorectal cancer (mCRC) to fight against chemoresistance. We previously reported the efficacy of raltitrexed plus oxaliplatin (HAI) in a retrospective series. We performed a randomized two-stage phase-II study to evaluate the efficacy of HAI of the combination of raltitrexed and oxaliplatin in refractory mCRC with only liver metastases in comparison with standard of care.